XBI Fact Sheet: State Street SPDR S&P Biotech ETF
Share
$140.18
close, Nov 20, 2026
Over the year to Nov 18, 2026, XBI returned +26.5% in total and charged 0.35% a year.
- 1-year total return
- +23.7%
- to Nov 20, 2026
- Expense ratio
- 0.35%
- a year
- Net assets
- $9.6bn
- on Nov 19, 2026
- Net flow, last 5 trading days
- −$303m
- daily basis to Nov 19, 2026
Growth of $10,000, 1 year
XBI $12,645 +26.5% · IVV $11,186 +11.9% · Total return, distributions reinvested, Nov 18, 2025 to Nov 18, 2026.
Returns
WindowTotal return
1 month−8.2%
3 months−15.4%
Year to date+15.1%
1 year+23.7%
3 years+95.9%
5 years+15.7%
Total return, distributions reinvested, each window to Nov 20, 2026.
Ten largest positions
HoldingWeight
MODERNA INC2.31%
TG THERAPEUTICS INC1.87%
BIOGEN INC1.84%
GILEAD SCIENCES INC1.80%
REGENERON PHARMACEUTICALS1.79%
EXELIXIS INC1.77%
ABBVIE INC1.77%
SPYRE THERAPEUTICS INC1.76%
INSMED INC1.76%
AMGEN INC1.75%
XBI top ten by weight, 18.4% of the fund, of its 165 equity positions, from the holdings published by its issuer for Nov 19, 2026.
Facts
Holds 165 stocks in biotech, 14% of its weight in S&P 500 companies · First traded Feb 6, 2006 · Benchmark Its own holdings, as of Nov 19, 2026